Navigation Links
Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development
Date:9/1/2009

COPENHAGEN and OSLO, September 1 /PRNewswire-FirstCall/ -- Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that it has appointed two experienced biotech executives to head its management team. Dr Robert Burns, previously CEO of Celldex Therapeutics Inc., has today assumed overall responsibility for Affitech as its new Chief Executive Officer. Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra Zeneca - Medimmune, also joins Affitech today as Senior Vice President of Research and Development. Dr Robert Burns takes over the Affitech CEO role from Dr Achim Kaufhold who, having successfully completed the recent combination of Affitech and Pharmexa, is leaving the Company. Dr Martin Welschof, Managing Director of Affitech Research AS, Oslo, continues in post.

Robert Burns is an experienced biotech business executive. He joins Affitech following the successful merger of Celldex Therapeutics and NASDAQ-listed Avant Immunotherapeutics. Prior to Celldex, Robert was Director of Technology Licensing at the Ludwig Institute for Cancer Research, where he was played key leadership roles in the spin-out of 3 successful companies, Piramed in the UK, Lymphatix in Finland and Recepta, an antibody therapeutics business, in Brazil. Prior to that he was Commercial Director at both Oxford Glycosciences and British Biotech. Robert is also non-executive Chairman of Haemostatix, an early stage company specialising in blood clotting products. Robert holds a BSc in Chemistry and a PhD in oligosaccharide analysis from The University of Birmingham.

Alexander Duncan is a leading antibody research scientist and business leader. At Astra Zeneca he was a member of AZ Discovery senior management team and SVP Biopharmaceuticals. He led the Cambridge UK Discovery site, previously Cambridge Antibody Technology (CAT), through its integration with Medimmune. Prior to its acquisition by
'/>"/>

SOURCE Affitech AS
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
2. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
3. Affitech Acquires Pharmexas Diabody Technology
4. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
5. Affitech Appoints Dr. Keith McCullagh as Chairman
6. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
7. ERT Appoints New Associate Director of Business Development - Japan
8. NeurogesX Appoints New Board Director and Audit Committee Chairman
9. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
10. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
11. Nucleix Appoints Meirav Chovav Vice President of Strategic Affairs and to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on Potassium Sulphate ... information, including its definition, classification, application, and industry ... the international market analysis, including China’s domestic market ... environment & economic situation analysis, the influence of ...
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... to continue integration and expansion of PFPA,s IT ... - SRA International, Inc.,(NYSE: SRX ), a ... solutions to government organizations and commercial clients,today announced ... the Pentagon Force,Protection Agency (PFPA) Life Safety Security ...
... 11, 2008 at 9:55 a.m. EST, CHICAGO, Nov. 4 ... that O.B. Parrish, the Company,s Chief,Executive Officer, and Donna Felch, ... Annual Global Investment Conference at 9:55,a.m. Eastern Time on November ... Palace Hotel in New York City., A live audio ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... a pivotal (Phase II/III) randomized trial using ... with head and neck cancers. The decision ... the Company,s Board of Directors from the ...
Cached Biology Technology:SRA Awarded $56 Million Contract by Pentagon Force Protection Agency 2The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference 2The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference 3Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2
(Date:7/25/2014)... SPRINGS, Florida , July 25, 2014 ... as more consumers are turning to digital technology for ... Inc. (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ... Inc. (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... journals need to ensure that their peer reviewers act ... to new guidelines launched by the Committee on Publication ... Reviewers set out the basic principles and standards that ... "Peer review plays an important role in ...
... power grids is challenging because fluctuating wind speed and ... varying power demand, many wind-farm managers end up wasting ... through active control including fully stopping turbines ... the power grid from spikes in supply. In a ...
... in a particular cellular pathway are linked with bladder ... early online in CANCER , a peer- reviewed ... help improve bladder cancer screening and treatment. Alterations ... is important for various cellular processes, have been implicated ...
Cached Biology News:Committee on Publication Ethics launches ethical guidelines for peer reviewers 2Genetic alterations linked with bladder cancer risk, recurrence, progression, and patient survival 2